These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 16613681

  • 1. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1655-8. PubMed ID: 17935664
    [Abstract] [Full Text] [Related]

  • 3. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Oct 05; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr 05; 29(4):217-21. PubMed ID: 18843972
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R, Redaelli S, Maino C, Bertuol S, Costantini C, Lazzarini A, Brivio L, Gorini M.
    Recenti Prog Med; 2005 Feb 05; 96(2):81-6. PubMed ID: 15844767
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P, Colantonio D, Collacciani A, Casale R, Natali G.
    Panminerva Med; 1991 Feb 05; 33(2):93-110. PubMed ID: 1923560
    [Abstract] [Full Text] [Related]

  • 11. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ.
    Zhonghua Yi Xue Za Zhi; 2010 Apr 13; 90(14):972-7. PubMed ID: 20646647
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors in multiple myeloma.
    Kyle RA.
    Stem Cells; 1995 Aug 13; 13 Suppl 2():56-63. PubMed ID: 8520513
    [Abstract] [Full Text] [Related]

  • 13. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
    Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.
    Ann Hematol; 2002 Jan 13; 81(1):33-6. PubMed ID: 11807633
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P, Collacciani A, Maccarone C, Casale R.
    Biomed Pharmacother; 1996 Jan 13; 50(1):29-35. PubMed ID: 8672729
    [Abstract] [Full Text] [Related]

  • 15. Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables--diagnostic and prognostic significance.
    Ffrench M, Ffrench P, Remy F, Chapuis-Cellier C, Wolowiec D, Ville D, Bryon PA.
    Am J Med; 1995 Jan 13; 98(1):60-6. PubMed ID: 7825620
    [Abstract] [Full Text] [Related]

  • 16. DNA-image cytometry and clinical staging systems in multiple myeloma.
    Kropff M, Leo E, Steinfurth G, Esselborn H, Adler CP, Böcking A.
    Anticancer Res; 1994 Jan 13; 14(5B):2183-8. PubMed ID: 7840520
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H, Nishimura J.
    Cancer; 2002 Apr 15; 94(8):2232-8. PubMed ID: 12001122
    [Abstract] [Full Text] [Related]

  • 18. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J, Wu XB, Zhou Y, Wang X, Chen JX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 15; 20(4):926-9. PubMed ID: 22931656
    [Abstract] [Full Text] [Related]

  • 19. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
    Pasqualetti P, Colantonio D, Casale R, Di Lauro G, Collacciani A, Festuccia V, Trotta A, Natali G.
    Ann Ital Med Int; 1990 Aug 15; 5(3 Pt 1):195-204. PubMed ID: 2288822
    [Abstract] [Full Text] [Related]

  • 20. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA.
    Cancer; 2010 Jan 01; 116(1):84-92. PubMed ID: 19862816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.